The Radiation Linear Accelerator Shared Service (RLASS) is a resource for supporting radiation studies for investigators at the University of Maryland School of Medicine, including the Mariene and Stewart Greenebaum Cancer Center (UMGCC). The shared service currently operates a state-of-the-art research megavoltage linear accelerator (Varian Medical Systems, Palo Alto, CA) that is capable of delivering photon (6-18 MV) and electron (6-18 MeV) radiation beams. This linear accelerator is equipped with state-of-the-art, onboard imaging capabilities that aid in accurate localization of radiation targets. With this combination of technologies, RLASS can replicate sophisticated treatment modalities that are offered as standard of care to patients undergoing radiation therapy. RLASS is a unique resource because most linear accelerators are typically utilized on a full-time basis for clinical radiation therapy treatments. RLASS offers cell culture irradiation, total and hemi-body irradiation, organ- and tissue-specific irradiation in the form of 3D conformal radiation therapy and intensity-modulated radiation therapy, treatment planning and 3D dose calculation capabilities, and onboard imaging. Highly skilled faculty and staff provide investigators at UMGCC with the expertise to design animal protocols and perform dosimetry calculations and measurements to ensure highly reliable estimates of whole-body, partial-body, and organ-specific doses. The effectiveness of this shared service can be gauged from the fact that it has supported the development of advanced radiation delivery and organ-motion management technologies. In addition, it has supported the development of complex nonhuman primate models of radiation-induced injury.

Public Health Relevance

The availability of the Radiation Linear Accelerator Shared Service is essential to advancing technical developments at UMGCC that will spur the creation of novel treatment radiation delivery methods. The radiation linear accelerator also provides a platform to evaluate models of intervention to prevent radiation injury.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA134274-05
Application #
8379055
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
5
Fiscal Year
2012
Total Cost
$81,430
Indirect Cost
$30,306
Name
University of Maryland Baltimore
Department
Type
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Nygård, Lotte; Vogelius, Ivan R; Fischer, Barbara M et al. (2016) Early lesion-specific (18)F-FDG PET response to chemotherapy predicts time to lesion progression in locally advanced non-small cell lung cancer. Radiother Oncol 118:460-4
Fox, Jennifer M; Moynihan, James R; Mott, Bryan T et al. (2016) Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs. Oncotarget 7:7268-79
Joseph, Ann Mary; Srivastava, Ratika; Zabaleta, Jovanny et al. (2016) Cross-talk between 4-1BB and TLR1-TLR2 Signaling in CD8+ T Cells Regulates TLR2's Costimulatory Effects. Cancer Immunol Res 4:708-16
Zandberg, Dan P; Liu, Sandy; Goloubeva, Olga et al. (2016) Oropharyngeal cancer as a driver of racial outcome disparities in squamous cell carcinoma of the head and neck: 10-year experience at the University of Maryland Greenebaum Cancer Center. Head Neck 38:564-72
Doshi, Kshama A; Trotta, Rossana; Natarajan, Karthika et al. (2016) Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress. Oncotarget 7:48280-48295
Ambulos Jr, Nicholas P; Schumaker, Lisa M; Mathias, Trevor J et al. (2016) Next-Generation Sequencing-Based HPV Genotyping Assay Validated in Formalin-Fixed, Paraffin-Embedded Oropharyngeal and Cervical Cancer Specimens. J Biomol Tech 27:46-52
Temburnikar, Kartik W; Ross, Christina R; Wilson, Gerald M et al. (2015) Antiproliferative activities of halogenated pyrrolo[3,2-d]pyrimidines. Bioorg Med Chem 23:4354-63
Kochel, Tyler J; Fulton, Amy M (2015) Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancer. Prostaglandins Other Lipid Mediat 116-117:99-103
Rasmussen, Jacob H; Vogelius, Ivan R; Aznar, Marianne C et al. (2015) Spatio-temporal stability of pre-treatment 18F-Fludeoxyglucose uptake in head and neck squamous cell carcinomas sufficient for dose painting. Acta Oncol 54:1416-22
Shih, Yu-Huan; Zhang, Yuji; Ding, Yonghe et al. (2015) Cardiac transcriptome and dilated cardiomyopathy genes in zebrafish. Circ Cardiovasc Genet 8:261-9

Showing the most recent 10 out of 207 publications